LON:HIK

Hikma Pharmaceuticals (HIK) Share Price, News & Analysis

Hikma Pharmaceuticals logo
GBX 1,682 +5.00 (+0.30%)
As of 12:42 PM Eastern

About Hikma Pharmaceuticals Stock (LON:HIK)

Advanced

Key Stats

Today's Range
1,667
▼
1,686
50-Day Range
1,498
▼
1,751
52-Week Range
1,187
▼
1,762
Volume
18.55 million shs
Average Volume
4.47 million shs
Market Capitalization
£3.48 billion
P/E Ratio
9.56
Dividend Yield
3.94%
Price Target
GBX 1,986.25
Consensus Rating
Buy

Company Overview

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing facilities, 9 R&D centres and 9,500 employees worldwide.

Hikma Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

HIK MarketRank™: 
3.202969640725 of 5 stars

Hikma Pharmaceuticals scored higher than 64% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Hikma Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Hikma Pharmaceuticals has a consensus price target of GBX 1,986.25, representing about 18.1% upside from its current price of GBX 1,682.

  • Amount of Analyst Coverage

    Hikma Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Hikma Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Hikma Pharmaceuticals is 9.56, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.92.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Hikma Pharmaceuticals is 9.56, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.16.

  • Price to Earnings Growth Ratio

    Hikma Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Hikma Pharmaceuticals has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for HIK.
  • Dividend Leadership

    Hikma Pharmaceuticals is a leading dividend payer. It pays a dividend yield of 3.94%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Hikma Pharmaceuticals does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Hikma Pharmaceuticals is 46.87%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about Hikma Pharmaceuticals' dividend.
  • News Sentiment

    Hikma Pharmaceuticals has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Hikma Pharmaceuticals this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Hikma Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    22.26% of the stock of Hikma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.62% of the stock of Hikma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Hikma Pharmaceuticals' insider trading history.
Receive HIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HIK Stock News Headlines

Top 3 British Biotech Stocks To Watch In November 2026
The next convergence is here
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
See More Headlines

HIK Stock Analysis - Frequently Asked Questions

Hikma Pharmaceuticals' stock was trading at GBX 1,550 at the start of the year. Since then, HIK stock has increased by 8.5% and is now trading at GBX 1,682.

Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hikma Pharmaceuticals investors own include Accenture (ACN), Chipotle Mexican Grill (CMG), Hudson Technologies (HDSN), Belden (BDC), Black Diamond Group (BDI), Gran Tierra Energy (GTE) and Transocean (RIG).

Company Calendar

Today
11/17/2026
Jefferies Global Healthcare Conference
11/18/2026
Investor update
11/24/2026
Status update
12/16/2026

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
LON:HIK
CIK
N/A
Fax
N/A
Employees
9,500
Year Founded
N/A

Price Target and Rating

High Price Target
GBX 2,050
Low Price Target
GBX 1,870
Potential Upside/Downside
+18.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
GBX 176
Trailing P/E Ratio
9.56
Forward P/E Ratio
N/A
P/E Growth
2.38
Net Income
£353.21 million
Net Margins
11.31%
Pretax Margin
N/A
Return on Equity
15.05%
Return on Assets
9.40%

Debt

Debt-to-Equity Ratio
77.57
Current Ratio
1.98
Quick Ratio
1.27

Sales & Book Value

Annual Sales
£3.42 billion
Price / Sales
1.02
Cash Flow
GBX 201.71 per share
Price / Cash Flow
8.34
Book Value
GBX 1,027.88 per share
Price / Book
1.64

Miscellaneous

Outstanding Shares
206,968,000
Free Float
N/A
Market Cap
£3.48 billion
Optionable
Not Optionable
Beta
0.65
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (LON:HIK) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners